The review concluded that pharmacological therapy in adolescent smokers did not statistically significantly effect smoking cessation with up to 26 weeks follow-up. There were few adverse events. The results may have been affected by small sample sizes. The review had some methodological problems and the limitations of the included studies should be borne in mind when interpreting the authors' conclusions.
Study selection
Randomised controlled trials (RCTs) of pharmacological smoking cessation interventions aimed at adolescent smokers (20 years or younger) that reported on rates of smoking cessation were eligible for inclusion. The primary outcome (abstinence rates) was validated by expired-air carbon monoxide or levels of saliva cotinine. Secondary outcomes were adverse events. Trials that did not report on smoking cessation as an outcome were excluded.
The included trials studied nicotine patch, nicotine nasal spray, nicotine gum and bupropion in combination with smoking cessation counselling versus placebo or placebo plus counselling or counselling alone. Participant ages were reported to range from 12 to 20 years. Trials were conducted between 1991 and 2009. Most trials were conducted in USA. England was also represented. Duration of therapy ranged from six to 12 weeks, where reported.
Two reviewers independently performed study selection. Disagreements were resolved by discussion.
Assessment of study quality
Trial quality was assessed using the Jadad scale of randomisation, blinding, allocation concealment and withdrawals/drop-outs to give a maximum score of 5. Trials that scored at least 4 were considered high quality.
The authors did not state how many reviewers performed quality assessment.
Data extraction
Data were extracted on smoking cessation and adverse events and were used to calculate relative risks (RRs) and 95% confidence intervals (CIs).
The authors did not state how many reviewers performed data extraction. Trial authors were contacted for missing information.
Methods of synthesis
A fixed-effect or random-effects meta-analysis, using intention-to-treat, was used to calculate pooled relative risks and 95% CIs. Statistical heterogeneity was assessed using I 2 . Subgroup analyses were conducted for type of pharmacological therapy, follow-up period and statistical analysis. Sensitivity analysis excluded a poor quality trial. Publication bias was assessed using funnel plots and Egger's test.
